Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E20.55 EPS (ttm)4.45 Insider Own0.40% Shs Outstand1.53B Perf Week2.93%
Market Cap139.57B Forward P/E10.26 EPS next Y8.91 Insider Trans7.64% Shs Float1.52B Perf Month11.29%
Income7.46B PEG0.77 EPS next Q1.80 Inst Own93.00% Short Float6.29% Perf Quarter23.46%
Sales17.44B P/S8.00 EPS this Y10.40% Inst Trans0.11% Short Ratio8.16 Perf Half Y15.98%
Book/sh10.72 P/B8.53 EPS next Y18.76% ROA28.60% Target Price108.65 Perf Year46.17%
Cash/sh6.28 P/C14.57 EPS next 5Y26.60% ROE57.30% 52W Range55.96 - 92.97 Perf YTD21.78%
Dividend- P/FCF- EPS past 5Y11.90% ROI18.70% 52W High-1.62% Beta0.72
Dividend %- Quick Ratio2.10 Sales past 5Y16.00% Gross Margin81.20% 52W Low63.44% ATR2.16
Employees6100 Current Ratio2.40 Sales Q/Q136.10% Oper. Margin56.20% RSI (14)66.00 Volatility2.18% 2.56%
OptionableYes Debt/Eq0.00 EPS Q/Q378.30% Profit Margin42.80% Rel Volume1.19 Prev Close89.84
ShortableYes LT Debt/Eq0.00 EarningsJul 23 AMC Payout0.00% Avg Volume11.70M Price91.46
Recom1.70 SMA204.18% SMA509.08% SMA20019.06% Volume14,066,500 Change1.80%
28-Jul-14Reiterated Maxim Group Buy $112 → $127
24-Jul-14Reiterated RBC Capital Mkts Outperform $96 → $102
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
26-Jul-13Reiterated RBC Capital Mkts Outperform $62 → $72
26-Jul-13Reiterated Barclays Overweight $65 → $68
26-Jul-13Downgrade Robert W. Baird Outperform → Neutral $55 → $65
29-Jul-14 03:11AM  $1,000 pill now hepatitis C treatment of choice AP
03:06AM  $1,000 pill now hepatitis C treatment of choice AP
28-Jul-14 04:40PM  Gilead's Oncology Drug Recommended for Approval in the EU Zacks
11:02AM  Why Gilead Sciences (GILD) Stock Is Up Today at TheStreet
08:55AM  5 Huge Biotech Catalysts Right Around the Corner for Top Stocks at 24/7 Wall St.
27-Jul-14 04:00PM  High cost of hepatitis C treatment pills is hard to swallow at Financial Times
04:00PM  Drug cocktails point the way towards relief for all hepatitis C sufferers at Financial Times
25-Jul-14 05:52PM  Politicizing Gilead's Research And Development Costs For Sovaldi Is A Reckless And Dangerous Misadventure at Forbes
02:52PM  [video] The push back on Sovaldi at CNBC
02:50PM  [video] The $84,000 drug debate at CNBC
12:15PM  [video] Drug costs hit insurers: Gilead still a buy? at CNBC
12:07PM  Did Gilead's Sovaldi Cause WellCare's Woes? at Barrons.com
11:46AM  AbbVie Beats Earnings Views, Sees Slower Humira Gain at Investor's Business Daily
08:32AM  Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger at Motley Fool
07:32AM  Gilead says EU Committee to recommend approval of leukemia drug at MarketWatch
07:25AM  Gilead receives positive opinion from CHMP for Zydelig at theflyonthewall.com
07:24AM  European CHMP Adopts Positive Opinion for Gileads Zydelig┬« (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma Business Wire
07:20AM  Europe backs new leukaemia drugs from J&J and Gilead Reuters
24-Jul-14 07:42PM  [$$] Beggar-Thy-Neighbor Medicine at The Wall Street Journal
07:08PM  Why Gilead Sciences, inc. Stock Was Flat Today at Motley Fool
05:07PM  Celgene, Alexion Beat Estimates, But Biotechs Fall at Investor's Business Daily
05:05PM  3 Crucial Quotes From Gilead Sciences Stock at Motley Fool
04:48PM  Understanding The Excitement That Surrounds Gilead at Seeking Alpha
04:02PM  What Gilead Stock's Latest Blockbuster Approval Means for Investors at Motley Fool
02:18PM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
02:05PM  3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmithKline at Motley Fool
01:50PM  A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval at Seeking Alpha
01:39PM  Your first trade for Friday at CNBC
12:59PM  [video] FMHR Final Trade: DAL, MCK, GILD & DNR at CNBC
12:30PM  Gilead: Even This Raging Bull Was Too Pessimistic at Seeking Alpha
11:44AM  Biotechs beat estimates, but the Street wants more at MarketWatch
11:39AM  Video: Celgene, Alexion Earnings Top, But Stocks Fall at Investor's Business Daily
11:39AM  Celgene, Alexion Earnings Top Street, But Stocks Fall at Investor's Business Daily
11:26AM  Why Gilead Is A Better Buy Than This Rival at Seeking Alpha
11:25AM  Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year at Seeking Alpha
11:11AM  Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside at TheStreet
10:29AM  This Eye-Popping Chart Of Ex-US Companies Shows Why People Are Freaking Out About 'Tax Inversions' Business Insider
10:28AM  Gilead Sciences - Sovaldi Momentum Continues, Appeal Remains at Seeking Alpha
10:00AM  Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic Accesswire
09:45AM  Today's Momo Momentum Stock To Watch: Gilead (GILD) at TheStreet
09:43AM  Gilead: Sovaldi Delivers Q2 Product Sales Of $3.5B... Enough Said at Seeking Alpha
09:38AM  Gilead Sciences: Truly a Value Stock at Barrons.com
09:38AM  Gilead Sciences: Now Can We Call It a Value Stock? at Barrons.com
08:50AM  Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar Zacks
08:21AM  Update: Gilead Sciences Earnings at Seeking Alpha
08:14AM  Biotech Giant Blows Away Expectations After Selling $3.5 Billion Of Its 'Wonder Drug' Business Insider
07:25AM  Gilead price target raised to $109 from $99 at Leerink at theflyonthewall.com
06:50AM  Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug Benzinga
12:24AM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
12:01AM  Patient Cures Spur Demand for $1,000 Hepatitis C Pill at Bloomberg
12:00AM  Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries Business Wire
23-Jul-14 10:58PM  Gilead Sciences' (GILD) CEO John Martin on Q2 2014 Results - Earnings Call Transcript Seeking Alpha
10:42PM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
09:47PM  Gilead Stock's Great Expectations and Giant Opportunity at Motley Fool
09:02PM  Gilead reports $5.8 billion in sales of hepatitis C drug at Los Angeles Times
08:51PM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
08:32PM  Gilead Sciences Crushes Second-Quarter Earnings at Motley Fool
08:00PM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
07:52PM  [$$] Hepatitis C Pill Rockets Gilead Into Big Leagues at The Wall Street Journal
06:59PM  Gilead profit more than quadruples on hep C drug AP
06:50PM  Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter Reuters
06:32PM  Biz Break: Gilead raking in massive cash from hepatitis C drug Sovaldi at San Jose Mercury News
06:21PM  [video] Gilead Sciences Beats Street and Sees Sovaldi Sales Double at TheStreet
06:17PM  Biogen, Gilead Earnings Crush Q2 Estimates Investor's Business Daily
06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool
06:02PM  [video] New Yorks Credit Rating Raised to AA+ by S&P at Bloomberg
05:49PM  Gilead trounces earnings views, but shares don't feel the after-hours love at MarketWatch
05:44PM  Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season at TheStreet
05:24PM  How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results? at TheStreet
05:16PM  Gilead Cures 9,000 Hep C Patientsand Collects $5.7 Billion at BusinessWeek
05:14PM  [video] Big Beat for Gilead on Rising Sovaldi Revenue at Bloomberg
05:12PM  [video] Why Gilead isn't soaring at CNBC
05:11PM  Gilead 2Q profit more than quadruples AP
04:54PM  Health insurer group asks Gilead to cut hepatitis C drug price Reuters
04:52PM  Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter Reuters
04:41PM  You Just Wont Believe Gileads Profit Margins at 24/7 Wall St.
04:39PM  [$$] Hepatitis Drug Continues Record Sales at The Wall Street Journal
04:35PM  Gilead Doubles 2014 Revenue Forecast on Sovaldi Sales at Bloomberg
04:31PM  Gilead Sciences Beats Earnings Forecasts, Sovaldi Sales Strong, Shares Slump at Barrons.com
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:18PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:18PM  Sales of Gilead hepatitis C drug Sovaldi soar in 2nd quarter Reuters
04:17PM  Gilead trounces estimates for earnings, sales, Sovaldi at MarketWatch
04:15PM  [$$] Hepatitis Drug Continues Record Sales at The Wall Street Journal
04:12PM  [video] Gilead's big Q2 beat at CNBC
04:09PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online
04:09PM  Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season at TheStreet
04:05PM  Gilead earnings beat Wall Street estimates at CNBC
04:05PM  Gilead Sciences Announces Second Quarter 2014 Financial Results Business Wire
03:39PM  FDA approves Gilead Sciences drug for 3 cancers AP
02:27PM  This Is What Happens When A New Drug Hits The Market And Nobody Knows What To Expect at Seeking Alpha
02:21PM  U.S. FDA approves Gilead blood cancer drug Zydelig Reuters
02:16PM  Does the Gilead Whisper Number Indicate Earnings Confidence? at Wall St. Cheat Sheet
01:30PM  4 ways Gileads earnings will impact every American at MarketWatch
01:18PM  Gilead's moment of truth arrives: How does Sovaldi impact earnings? at MarketWatch
12:57PM  FDA approves Gilead Sciences drug for 3 cancers AP
12:40PM  [video] Biotech blowout: Biogen & Gilead at CNBC
12:02PM  Gileads earnings report affects every American at MarketWatch
11:56AM  Biogen Trounces Q2 Estimates As Tecfidera Outperforms at Investor's Business Daily
11:48AM  U.S. Food and Drug Administration Approves Gileads Zydelig┬« (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma Business Wire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Option Exercise21.5831,000668,825118,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Option Exercise8.01140,6251,125,7034,396,892Feb 05 06:53 PM
MARTIN JOHN CChairman and CEOFeb 03Sale79.96140,62511,244,0894,256,267Feb 05 06:53 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Sale80.7833,0002,665,59385,516Feb 05 06:34 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Option Exercise16.40100,0001,639,500316,418Jan 27 08:07 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Sale81.44100,0008,144,150216,418Jan 27 08:07 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Option Exercise19.94120,0002,392,393152,938Jan 22 07:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Sale80.00120,0009,600,00032,938Jan 22 07:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Option Exercise14.5090,0001,305,22590,000Jan 16 02:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Sale74.2390,0006,681,1470Jan 16 02:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.11111,0002,121,519145,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise8.01140,6251,125,7034,197,746Jan 06 05:38 PM
Washington Robin LSVP, CFOJan 02Option Exercise22.4935,600800,49035,600Jan 06 05:39 PM
Washington Robin LSVP, CFOJan 02Sale75.0335,6002,671,2140Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Sale75.02140,62510,550,1804,057,121Jan 06 05:38 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale75.01113,0008,476,56432,938Jan 06 05:39 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Option Exercise16.4075,0001,229,625236,840Dec 24 01:41 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Sale74.1975,0005,564,453161,840Dec 24 01:41 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Option Exercise14.5090,0001,305,22590,000Dec 18 02:16 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Sale71.7590,0006,457,9410Dec 18 02:16 PM
MARTIN JOHN CChairman and CEODec 02Option Exercise7.63282,2422,154,2124,339,363Dec 04 03:55 PM
MARTIN JOHN CChairman and CEODec 02Sale74.26282,24220,960,6974,057,121Dec 04 03:55 PM
MILLIGAN JOHN FPresident and COONov 25Option Exercise7.8125,588199,954590,362Nov 26 06:20 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Option Exercise16.4075,0001,229,625236,840Nov 25 03:25 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Sale74.3475,0005,575,549161,840Nov 25 03:25 PM